Filing Details

Accession Number:
0001437749-22-020338
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-08-12 16:02:19
Reporting Period:
2022-08-10
Accepted Time:
2022-08-12 16:02:19
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
842023 Bio-Techne Corp TECH Biological Products, (No Disgnostic Substances) (2836) 411427402
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1208906 L John Higgins 11085 North Torrey Pines Road
Suite 300
La Jolla CA 92037
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-08-10 3,400 $66.90 8,006 No 4 M Direct
Common Stock Disposition 2022-08-10 900 $373.99 7,106 No 4 S Direct
Common Stock Disposition 2022-08-10 100 $374.90 7,006 No 4 S Direct
Common Stock Disposition 2022-08-10 992 $380.15 6,014 No 4 S Direct
Common Stock Disposition 2022-08-11 504 $385.47 5,510 No 4 S Direct
Common Stock Disposition 2022-08-11 8 $380.71 5,502 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2022-08-10 3,400 $0.00 3,400 $66.90
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2012-10-25 2022-10-24 No 4 M Direct
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock Stock Option (right to buy) $87.39 2013-10-31 2023-10-30 4,000 4,000 Direct
Common Stock Stock Option (right to buy) $91.78 2014-10-30 2024-10-30 4,000 4,000 Direct
Common Stock Stock Option (right to buy) $87.34 2016-10-29 2025-10-28 4,260 4,260 Direct
Common Stock Stock Option (right to buy) $101.19 2017-10-26 2026-10-26 3,985 3,985 Direct
Common Stock Stock Option (right to buy) $125.05 2018-10-25 2027-10-27 3,125 3,125 Direct
Common Stock Stock Option (right to buy) $179.84 2019-10-24 2028-10-25 1,898 1,898 Direct
Common Stock Stock Option (right to buy) $201.64 2020-10-24 2029-10-24 2,011 2,011 Direct
Common Stock Stock Option (right to buy) $255.69 2021-10-28 2030-10-29 1,507 1,507 Direct
Common Stock Stock Option (right to buy) $515.24 2031-10-28 633 633 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2023-10-30 4,000 4,000 Direct
2024-10-30 4,000 4,000 Direct
2025-10-28 4,260 4,260 Direct
2026-10-26 3,985 3,985 Direct
2027-10-27 3,125 3,125 Direct
2028-10-25 1,898 1,898 Direct
2029-10-24 2,011 2,011 Direct
2030-10-29 1,507 1,507 Direct
2031-10-28 633 633 Direct
Footnotes
  1. The option vests on the earlier of the one year anniversary of the grant date (10/28/21) or the date of Bio-Techne's 2022 annual meeting of shareholders.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 373.8600 to 374.3300, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 374.8950 to 374.9000, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 380.0000 to 380.4400, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 385.2900 to 385.8900, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.